+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Atherosclerosis Drugs Market by Drug Class, Administration Route, Distribution Channel, Dosage Form, End User - Global Forecast to 2030- Product Image
Atherosclerosis Drugs Market by Drug Class, Administration Route, Distribution Channel, Dosage Form, End User - Global Forecast to 2030- Product Image
Sale

Atherosclerosis Drugs Market by Drug Class, Administration Route, Distribution Channel, Dosage Form, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967871
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The atherosclerosis drugs market is evolving rapidly, shaped by innovation in drug development and increasing pressure on healthcare systems to manage the global cardiovascular disease burden. Senior leaders require in-depth insights that connect emerging therapeutic trends, regulatory landscapes, and market growth to informed strategic decision-making.

Market Snapshot: Atherosclerosis Drugs Market Outlook

The Atherosclerosis Drugs Market grew from USD 23.82 billion in 2024 to USD 25.25 billion in 2025. It is expected to continue growing at a CAGR of 5.71%, reaching USD 33.25 billion by 2030. This steady expansion is fueled by rising incidence of atherosclerotic cardiovascular disease, ongoing innovation in pharmacological therapies, and increased attention to early intervention in at-risk populations. The market gains momentum as stakeholders introduce new lipid-modifying agents and deploy next-generation technologies to optimize treatment adherence and outcomes.

Scope & Market Segmentation

This comprehensive report provides actionable segment-level analysis to guide product strategy, investment, and market entry decisions.

  • Drug Classes: Statins (e.g., Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin), PCSK9 inhibitors (Alirocumab, Evolocumab), fibrates (Fenofibrate, Gemfibrozil), niacin (extended and immediate release), omega-3 fatty acids (Docosahexaenoic Acid, Eicosapentaenoic Acid), bile acid sequestrants (Cholestyramine, Colesevelam, Colestipol)
  • Administration Routes: Injectable (intravenous) and oral (capsule, tablet) therapies targeting multiple patient profiles
  • Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy for broad access
  • Dosage Forms: Capsule, injection, and tablet formats for patient-centered approaches
  • End Users: Clinics, hospitals, and home care settings reflecting diverse treatment sites
  • Geographies: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (UK, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Companies: Amgen Inc., Novartis AG, Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Regeneron Pharmaceuticals, Merck & Co., Bristol-Myers Squibb Company, Bayer AG, Johnson & Johnson

Key Takeaways for Senior Decision-Makers

  • Growth is propelled by more complex patient demographics, including aging populations and the rising prevalence of comorbidities that heighten atherosclerosis risk.
  • Targeted therapies, such as monoclonal antibodies against PCSK9, and advances in gene editing, are expanding the clinical arsenal and supporting personalized treatment plans.
  • Digital health integration—such as remote lipid monitoring and telehealth consultations—is facilitating real-time data capture and risk management.
  • Pharmaceutical manufacturers are investing in multi-modal distribution and flexible dosage forms to improve patient adherence and clinical effectiveness.
  • Shifting reimbursement approaches, especially value-based pricing models, are prompting organizations to demonstrate measurable patient outcomes and engage in outcome-based contracts.
  • Strategic partnerships between industry players, digital health firms, and research institutions are accelerating development timelines and access to market.

Tariff Impact: US Market Implications in 2025

The introduction of new US tariffs in 2025 created cost and supply chain pressures throughout the atherosclerosis drug sector. Companies have responded by re-evaluating sourcing strategies, negotiating supplier agreements, and incrementally investing in supply chain resilience. These actions emphasize the market’s vulnerability to global economic shifts and the need for robust procurement and risk management strategies to ensure continuity of patient care and stable pricing models.

Methodology & Data Sources

Findings are grounded in primary interviews with industry experts, surveys with procurement specialists and patient advocacy organizations, and comprehensive review of scientific literature, regulatory filings, and company disclosures. Data triangulation reinforces analytical integrity and underpins robust, actionable recommendations.

Why This Report Matters

  • Informs executive decision-making with up-to-date, validated market intelligence on competitive positioning, growth drivers, and segment priorities.
  • Highlights tangible strategic moves, such as precision medicine integration and digital health partnerships, to support value creation and sustained leadership.
  • Assists organizations in navigating evolving policy, pricing, and access challenges in global and regionally diverse markets.

Conclusion

This report synthesizes current trends, segment opportunities, and market forces to support senior executives in formulating competitive, sustainable growth strategies. The complexities of the atherosclerosis drugs landscape underscore the importance of agility and multidisciplinary collaboration.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Atherosclerosis Drugs Market, by Drug Class
8.1. Introduction
8.2. Bile Acid Sequestrants
8.2.1. Cholestyramine
8.2.2. Colesevelam
8.2.3. Colestipol
8.3. Fibrates
8.3.1. Fenofibrate
8.3.2. Gemfibrozil
8.4. Niacin
8.4.1. Extended Release
8.4.2. Immediate Release
8.5. Omega-3 Fatty Acids
8.5.1. Docosahexaenoic Acid
8.5.2. Eicosapentaenoic Acid
8.6. PCSK9 Inhibitors
8.6.1. Alirocumab
8.6.2. Evolocumab
8.7. Statins
8.7.1. Atorvastatin
8.7.2. Pravastatin
8.7.3. Rosuvastatin
8.7.4. Simvastatin
9. Atherosclerosis Drugs Market, by Administration Route
9.1. Introduction
9.2. Injectable
9.2.1. Intravenous
9.3. Oral
9.3.1. Capsule
9.3.2. Tablet
10. Atherosclerosis Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Atherosclerosis Drugs Market, by Dosage Form
11.1. Introduction
11.2. Capsule
11.3. Injection
11.4. Tablet
12. Atherosclerosis Drugs Market, by End User
12.1. Introduction
12.2. Clinic
12.3. Home Care
12.4. Hospital
13. Americas Atherosclerosis Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Atherosclerosis Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Atherosclerosis Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Amgen Inc.
16.3.2. Novartis AG
16.3.3. Pfizer Inc.
16.3.4. Sanofi S.A.
16.3.5. AstraZeneca PLC
16.3.6. Regeneron Pharmaceuticals, Inc.
16.3.7. Merck & Co., Inc.
16.3.8. Bristol-Myers Squibb Company
16.3.9. Bayer AG
16.3.10. Johnson & Johnson
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ATHEROSCLEROSIS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ATHEROSCLEROSIS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ATHEROSCLEROSIS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ATHEROSCLEROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ATHEROSCLEROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ATHEROSCLEROSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 82. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 84. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 85. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 86. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 87. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 89. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 90. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 91. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 92. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 94. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 98. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 99. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 101. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 103. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 104. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 105. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 107. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 163. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 164. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 165. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 166. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 167. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 168. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 169. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 170. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 171. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 173. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 176. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 177. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 178. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 179. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 180. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 181. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 182. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 183. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 184. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 186. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 201. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 202. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 203. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 204. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 205. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 206. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 207. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 208. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 209. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 210. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 212. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 215. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 216. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 217. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 218. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 219. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 220. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 221. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 222. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 223. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 225. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 266. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 267. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 268. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 269. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 270. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 271. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 272. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 273. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 274. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 275. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 277. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 279. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 280. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 281. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 282. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 292. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 293. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 294. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 295. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 296. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 297. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 298. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 299. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 300. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 301. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 303. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 305. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 306. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 307. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 308. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 309. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 310. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 311. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 312. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 313. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 314. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 315. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 316. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 318. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 319. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 320. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 321. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 322. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 323. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2030 (USD MILLION)
TABLE 324. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 325. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 326. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 327. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 329. SWEDEN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 330. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 331. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2030 (USD MILLION)
TABLE 332. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2030 (USD MILLION)
TABLE 333. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2030 (USD MILLION)
TABLE 334. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2030 (USD MILLION)
TABLE 335. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 336. NIGERIA A

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Atherosclerosis Drugs market report include:
  • Amgen Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • AstraZeneca PLC
  • Regeneron Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Johnson & Johnson

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 25.25 Billion
Forecasted Market Value ( USD ) by 2030 $ 33.25 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Atherosclerosis Drugs Market Report 2025 - Product Image

Atherosclerosis Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Atherosclerosis Drugs - Global Strategic Business Report - Product Image

Atherosclerosis Drugs - Global Strategic Business Report

  • Report
  • 389 Pages
  • Global
From
Atherosclerosis Therapeutics - Global Strategic Business Report - Product Image

Atherosclerosis Therapeutics - Global Strategic Business Report

  • Report
  • 181 Pages
  • Global
From
Atherosclerosis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035 - Product Image

Atherosclerosis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Atherosclerosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Atherosclerosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.